Group Radical Openness: A feasibility study

Wykaz prac cytowanych wewnątrz artykułu (relacja cites → Publication), pobrany ze zweryfikowanych metadanych PubMed / Crossref:

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   Lista referencji z PubMed
2. Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol. 2017;115(5):564–79.
   Lista referencji z PubMed
3. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.
   Lista referencji z PubMed
4. Herskovic A, Russell W, Liptay M, Fidler MJ, al‐Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23(5):1095–103.
   Lista referencji z PubMed
5. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta‐analysis. Lancet Oncol. 2011;12(7):681–92.
   Lista referencji z PubMed
6. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
   Lista referencji z PubMed
7. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta‐analysis. Lancet Oncol. 2007;8(3):226–34.
   Lista referencji z PubMed
8. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.
   Lista referencji z PubMed
9. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long‐term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.
   Lista referencji z PubMed
10. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47(3):354–60.
    Lista referencji z PubMed
11. Klevebro F, von Dobeln GA, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro‐oesophageal junction. Ann Oncol. 2016;27(4):660–7.
    Lista referencji z PubMed
12. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized. Open‐Label Clinical Trial J Clin Oncol. 2018;36(27):2796–803.
    Lista referencji z PubMed
13. Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32(23):2416–22.
    Lista referencji z PubMed
14. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.
    Lista referencji z PubMed
15. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5‐fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.
    Lista referencji z PubMed
16. Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104(11):1455–60.
    Lista referencji z PubMed
17. Zhao Y, Dai Z, Min W, Sui X, Kang HF, Zhang YF, et al. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial. J Thorac Oncol. 2015;10(9):1349–56.
    Lista referencji z PubMed
18. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993;20(4 Suppl 3):1–15.
    Lista referencji z PubMed
19. Fjallskog ML, Frii L, Bergh J. Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet. 1993;342(8875):873.
    Lista referencji z PubMed
20. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(5 Suppl):S11–4.
    Lista referencji z PubMed
21. Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2007;14(5):301–8.
    Lista referencji z PubMed
22. Zhang B, Qi L, Wang X, Xu J, Liu Y, Mu L, et al. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma. Cancer Commun (Lond). 2020;40(12):711–20.
    Lista referencji z PubMed
23. Jimenez‐Lopez J, Bravo‐Caparros I, Cabeza L, et al. Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes. Biomed Pharmacother. 2021;133:111059.
    Lista referencji z PubMed
24. Bi Z, Chen P, Liu YB, Zhao T, Sun X, et al. Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer. Breast Cancer Res Treat. 2020;184(2):397–405.
    Lista referencji z PubMed
25. Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care? Cancer Control. 2013;20(2):89–96.
    Lista referencji z PubMed
26. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg. 1997;114(2):210–7.
    Lista referencji z PubMed
27. Maipang T, Vasinanukorn P, Petpichetchian C, Chamroonkul S, Geater A, Chansawwaang S, et al. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol. 1994;56(3):191–7.
    Lista referencji z PubMed
28. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91(11):2165–74.
    Lista referencji z PubMed
29. Wang F, Wang YM, He W, Li XK, Peng FH, Yang XL, et al. Chemoradiotherapy followed by surgery could improve the efficacy of treatments in patients with resectable esophageal carcinoma. Chin Med J (Engl). 2013;126(16):3138–45.
    Lista referencji z PubMed
30. Cao W, Xu C, Lou G, Jiang J, Zhao S, Geng M, et al. A phase II study of paclitaxel and nedaplatin as first‐line chemotherapy in patients with advanced esophageal cancer. Jpn J Clin Oncol. 2009;39(9):582–7.
    Lista referencji z PubMed
31. Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H, et al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 2013;30(1):343.
    Lista referencji z PubMed
32. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338(1–2):317–26.
    Lista referencji z PubMed
33. Hong SS, Choi JY, Kim JO, Lee MK, Kim SH, Lim SJ. Development of paclitaxel‐loaded liposomal nanocarrier stabilized by triglyceride incorporation. Int J Nanomedicine. 2016;11:4465–77.
    Lista referencji z PubMed
34. Liu S, Ren SN, Ding WX, Ge XL, Cao YD, Zhang S, et al. Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity‐modulated radiotherapy. Ann Transl Med. 2019;7(14):331.
    Lista referencji z PubMed
35. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long‐term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.
    Lista referencji z PubMed
36. Pasini F, de Manzoni G, Zanoni A, Grandinetti A, Capirci C, Pavarana M, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5‐fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long‐lasting pathological complete response: a phase 2 study. Cancer. 2013;119(5):939–45.
    Lista referencji z PubMed
37. Lorenzen S, Thuss‐Patience P, Al‐Batran SE, et al. Impact of pathologic complete response on disease‐free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel‐based chemotherapy. Ann Oncol. 2013;24(8):2068–73.
    Lista referencji z PubMed
38. Medical Research Council Oesophageal Cancer Working G . Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–33.
    Lista referencji z PubMed
39. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979–84.
    Lista referencji z PubMed
40. Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, et al. Encouraging pathological complete response rate from neoadjuvant chemotherapy with albumin‐bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous carcinoma: preliminary outcome of a retrospective study. Cancer Manag Res. 2021;13:2163–70.
    Lista referencji z PubMed
41. Gong L, Mao W, Chen Q, Jiang Y, Fan Y. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab‐paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study. Cancer Chemother Pharmacol. 2019;83(4):639–47.
    Lista referencji z PubMed
42. Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, et al. Phase II study of neoadjuvant therapy with nab‐paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget. 2016;7(31):50624–34.
    Lista referencji z PubMed
43. Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde C, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
    Lista referencji z PubMed
44. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.
    Lista referencji z PubMed
45. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.
    Lista referencji z PubMed
46. Yang G, Su X, Yang H, Luo G, Gao C, Zheng Y, et al. Neoadjuvant programmed death‐1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma. Ann Transl Med. 2021;9(15):1254.
    Lista referencji z PubMed
47. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, et al. Highlights of the EORTC St. Gallen international expert consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer ‐ differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48(16):2941–53.
    Lista referencji z PubMed
48. Tang HR, Ma HF, An SM, Badakhshi H, Deng JY, Zhang JH, et al. A phase II study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma. Am J Clin Oncol. 2016;39(4):350–4.
    Lista referencji z PubMed
49. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera‐Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.
    Lista referencji z PubMed
50. Hirao M, Ando N, Tsujinaka T, Udagawa H, Yano M, Yamana H, et al. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg. 2011;98(12):1735–41.
    Lista referencji z PubMed

Dokładne dopasowania identyfikatorów

Nie znaleziono dopasowań w tej grupie.

Kandydaci do ręcznej kontroli

Nie znaleziono dopasowań w tej grupie.

Konflikty

Nie znaleziono dopasowań w tej grupie.

Podobieństwo nie scala rekordów i nie potwierdza tożsamości publikacji.

Zakres: zweryfikowane twierdzenia i powiązania w opublikowanych artykułach serwisu.